The State of Arizona is investing in the future of veteran health with a $150,000 appropriation to ASTO for FY26. Managed by the Opportunity Through Entrepreneurship Foundation (OTEF), these funds empower the AZAdvances initiative to bridge the gap between life science entrepreneurship and patient care. By accelerating health innovations and strengthening the local workforce, OTEF/AZAdvances and the Arizona Health Innovation Trust Fund (AHIT) are working to ensure a healthier future for all Arizonans. 

The 2025-2026 AZAdvances Improving Health for Veterans were awarded to Life365, MiiHealth.AI, Regenesis Medical, and the  Ndee Bikiyaa (The People’s Farm), White Mountain Apache Tribe. 
Continue reading→

• Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
• Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership
• Company reinforces commitment to U.S. manufacturing and American jobs

Continue reading→

• Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation
• Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s recently-launched direct-to-patient program
• Company commitment to U.S. manufacturing, infrastructure, and R&D reaffirmed, building on the recent $50 billion investment announcement and recent groundbreaking of new manufacturing facility in North Carolina
• Government exempts Genentech portfolio from tariffs, enabling Genentech’s continued investment and expansion of its manufacturing footprint in the U.S.

Continue reading→

• Voluntary agreement delivers on all four of President Trump’s requests and reduces the cost of medicines for Americans
• Includes products used to treat the more than 40 million patients in the U.S. who suffer from respiratory conditions such as asthma and COPD
• Builds on GSK’s decades-long commitment to make products accessible worldwide to those who need them

Continue reading→

Underscores Long-Standing Commitment to Investing in Innovation and U.S. ManufacturingContinue reading→

Agreement Provides Tariff Relief for a 3-Year PeriodContinue reading→

• Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
• Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program
• Merck has committed more than $70 billion in U.S. investments to boost domestic production and innovation

Continue reading→

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing

Additional Novartis medicines will be made available through direct-to-patient platforms in 2026

Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines

Continue reading→

Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technologyContinue reading→

Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix has been awarded three new R01 grants from the National Institutes of Health (NIH), the gold standard of federally funded research awards.Grant funding will advance pediatric lung and spine research.Continue reading→